COVID-19: clinical trial on hydroxychloroquine at the MUHC
Researchers from the Research Institute of the McGill University Health Center have launched a clinical trial to assess whether hydroxychloroquine (HCQ) can prevent people from contracting COVID-19 after exposure to the SARS-CoV2 virus and if it can reduce complications and deaths related to the disease.
L has HCQ is approved by Health Canada and used to treat malaria and certain autoimmune diseases such as lupus.
“Researchers hope to show that HCQ can reduce the risk of spreading the virus in people exposed to infected people, reduce the progression to serious illness requiring hospitalization and respiratory support, and decrease the number of deaths from COVID- 19, ”said a press release.
The study began with the registration of healthcare workers who were exposed to COVID-19. It is now open to all eligible adults in the province of Quebec.
Participants are eligible for the treatment component of the clinical trial if they have a confirmed diagnosis of COVID-19, if their symptoms have started in the last three or four days, and if they are in home isolation.
To be eligible for the prevention component, participants must live with a person suffering from COVID-19, or have had a high-risk exposure to a person suffering from COVID-19 in the last three or four days and not yet show symptoms.
Those who meet these criteria and wish to participate in the clinical trial can visit covid-19research.ca .